Search
Call for Proposals: 2024 Police, Treatment, and Community Collaborative (PTACC) International Deflection and Pre-arrest Diversion Summit
Proposals are now being accepted for the 2024 Police, Treatment, and Community Collaborative (PTACC) International Deflection and Pre-arrest Diversion Summit. All submissions must be uploaded by April 19, 2024 at 12:00 PM PDT in order to be...
Residential addiction treatment for adolescents is scarce and expensive
Science of Self-Care: How It Helps and Why It Matters
Synthetic Opioids: Navigating a Changing Landscape in the Treatment of Opioid Use Disorder
Alarming Statistics: Over One Million Young Drivers Imperil Lives with Marijuana and Alcohol Behind the Wheel
Driving under the influence (DUI) of psychoactive substances is an issue of paramount concern in both public health and the criminal justice system. It affects millions of Americans yearly, and while there is extensive research on DUI among...
Substance Use Disorders (SUD) and Type 2 Diabetes: Integration of Evidence-Based Diabetes Care to Promote Quality Health Outcomes
Connecting Communities to Substance Use Services: Practical Approaches for First Responders
Abstract
During their day-to-day work, first responders such as law enforcement officers, firefighters, and emergency medical services (EMS) personnel often encounter people who use drugs (PWUD), including alcohol, opioids, stimulants...
Fentanyl, informations du NIDA
Le fentanyl est un opioïde synthétique puissant similaire à la morphine, mais 50 à 100 fois plus puissant. C’est un médicament d’ordonnance qui est aussi parfois utilisé illégalement. Comme la morphine, il est généralement prescrit aux...
Fentanyl DrugFacts
Fentanyl is a powerful synthetic opioid that is similar to morphine but is 50 to 100 times more potent. It is a prescription drug that is also made and used illegally. Like morphine, it is a medicine that is typically used to treat patients...
FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder
For Immediate Release: May 23, 2023
Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD)...
La FDA aprueba una nueva opción de tratamiento con buprenorfina para el trastorno por consumo de opioides
Para publicación inmediata: 24 de mayo del 2023
Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) aprobó la inyección subcutánea (para uso por debajo de la piel) de Brixadi...
PTACC Annual Deflection Summit Call for International Presenters
Proposals are now being accepted for the 2023 Police, Treatment, and Community Collaborative’s (PTACC) National Deflection and Pre-arrest Diversion Summit.
All submissions must be uploaded by May 5, 2023 at 2:00 EDT in order to be...
National Substance Use and Mental Health Services Survey (N-SUMHSS), 2021: Data on Substance Use and Mental Health Treatment Facilities
The N‑SUMHSS is a voluntary annual survey of all active substance use and mental health facilities in the United States, its territories, and D.C. The annual report presents findings on the general profile of substance use and mental health...
Gestion du sevrage alcoolique ambulatoire : un outil pour les milieux de pratique mondiaux
Resilience in Leadership: Key Behaviors for Self-Care and Caring for Others
ICUDDR Novembre 2022 Newsletter
Nous sommes heureux de vous présenter notre newsletter de novembre 2022, profitez des articles et partagez-les à votre guise. Merci!
The Substance Use Professional’s Guide to Addressing Medical Cannabis in Substance Use Treatment Settings
New Training for Medical Providers: Integrating Addiction Medicine With Treatment Courts
NADCP is partnering with the American Society of Addiction Medicine (ASAM) to offer a new training for medical providers working with participants in drug treatment courts. This training will help medical providers learn how to successfully...
Le NIDA publie son plan stratégique 2022-2026
Cette semaine, le NIDA publie son plan stratégique pour l’exercice 2022-2026. La planification stratégique est un processus que tous les instituts des NIH effectuent tous les cinq ans, afin de faire le point sur l’état actuel de la...
Share the Knowledge: ISSUP members can post in the Knowledge Share – Sign in or become a member